Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test for Tagrisso
Thermo Fisher Scientific is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for Tagrisso.
Read MorePosted by Andy Lundin | Jan 24, 2023 | Lung Cancer |
Thermo Fisher Scientific is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for Tagrisso.
Read MorePosted by Andy Lundin | Jan 23, 2023 | Immunoassay Reagents & test Kits, Lung Cancer, Sequencing Systems |
The liquid biopsy ctDx FIRST test is FDA approved as a companion diagnostic for advanced non-small cell lung cancer (NSCLC) patients.
Read MorePosted by Andy Lundin | Jan 11, 2023 | Dementias & Alzheimer’s |
A U.S. patent that focuses on the development of a novel blood-based biomarker for the early detection of Alzheimer’s has been issued.
Read MorePosted by Andy Lundin | Jan 10, 2023 | Lung Cancer |
Micronoma announced its OncobiotaLUNG assay received the Breakthrough Device Designation from the U.S. FDA for lung carcinoma detection.
Read MorePosted by Andy Lundin | Jan 9, 2023 | Lung Cancer |
PrognomiQ unveiled results from multi-omics study demonstrating the power of diverse molecular biomarkers in the early cancer detection.
Read More